studies

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), ipilimumab plus SoC vs. all, meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220 - treatments: 868